Silence Therapeutics (SLN) Assets (2024 - 2026)

Silence Therapeutics (SLN) has 3 years of Assets data on file, last reported at $115.1 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 37.87% year-over-year to $115.1 million; the trailing twelve-month figure through Mar 2026 stood at $115.1 million (down 37.87% YoY), and the FY2025 full-year result was $131.4 million, down 35.13% from the prior year.
• Assets retreated to $115.1 million in Q1 2026, from $131.4 million in the prior quarter.
• In the past five years, Assets ranged from a high of $202.6 million in Q4 2024 to a low of $115.1 million in Q1 2026.
• A 3-year average of $157.8 million and a median of $156.0 million in 2025 frame the typical range for Assets.
• Across the five-year window, Assets tumbled 35.13% in 2025 and tumbled 37.87% in 2026, its largest moves.
• Tracing SLN's Assets over 3 years: stood at $202.6 million in 2024, then plunged by 35.13% to $131.4 million in 2025, then retreated by 12.42% to $115.1 million in 2026.
• Business Quant data shows SLN's Assets at $115.1 million in Q1 2026, $131.4 million in Q4 2025, and $146.8 million in Q3 2025.